Skip to main content

Table 1 Baseline characteristics of participants in a single-center cross-sectional study of hypozincemia and aortic stenosis prevalence

From: The association between hypozincemia and aortic stenosis prevalence in hemodialysis patients: a single-center cross-sectional study

  Zn ≤ 48 (1st decile) 48 < Zn (2nd-10th deciles) P value
Number of patients 12 (13%) 81 (87%)  
AS 6 (50%) 13 (16%) < 0.01
Surgical history of AS 1 (8.3%) 4 (4.9%) 0.58
Age 75.3 ± 12.5 70.6 ± 9.9 0.034
Male 9 (75%) 45 (56%) 0.21
Height (cm) 164.9 ± 8.7 159.8 ± 8.8 0.1
Dw (kg) 57.5 ± 10.9 53.4 ± 11.3 0.19
Diabetes 3 (25%) 22 (27%) 0.88
Dialysis vintage (year) 11.3 ± 8.7 10.9 ± 7.3 0.94
Zn (μg/dL) 45.0 ± 4.3 63.7 ± 13.1 < 0.01
ALB (g/dL) 3.2 ± 0.4 3.5 ± 0.3 0.043
Hb (g/dL) 11.1 ± 1.4 11.4 ± 1.0 0.1
Ferritin (ng/mL) 135.6 ± 45.1 119.0 ± 91.2 0.12
Cre (mg/dL) 9.4 ± 1.7 10.5 ± 2.4 0.09
Ca (mg/dL) 9.3 ± 0.4 9.3 ± 0.6 0.72
P (mg/dL) 5.0 ± 0.8 5.1 ± 1.6 0.86
Ca × P 46 ± 7.5 47.5 ± 14 0.95
P ave 5.2 ± 0.8 5.2 ± 1.0 0.83
K (mEq/L) 5.0 ± 0.6 5.0 ± 0.7 0.87
Mg (mg/dL) 2.5 ± 0.2 2.8 ± 0.4 < 0.01
Cu (μg/dL) 90 ± 23 87.1 ± 19.1 0.68
iPTH (pg/mL) 184.0 ± 112.1 133.7 ± 105.3 0.11
LDL-chol (mg/dL) 75.9 ± 18.9 82.9 ± 25.3 0.29
TAC-BUN 48.2 ± 6.6 48.5 ± 9.6 1
Kt/V for urea 1.44 ± 0.18 1.54 ± 0.19 0.17
SBP (mmHg) 137.7 ± 19.0 142.8 ± 16.7 0.43
Drug
 Vitamin D 10 (83%) 76 (92%) 0.12
 Calcium-containing phosphate binder 8 (67%) 51 (61%) 0.51
 ACE/ARB 9 (75%) 48 (58%) 0.34
 Calcimimetics 7 (58%) 41 (49%) 0.71
 P absorbentsa 1.5 ± 0.8 2.1 ± 0.9 0.024
 Warfarin 5 (42%) 16 (19%) 0.1
 Statins 5 (41.7%) 24 (29.6%) 0.4
Past history
 IHD 5 (41.7 %) 22 (27.2 %) 0.3
 CVD 2 (16.6 %) 14 (17.3 %) 0.96
 ASO 4 (33.3 %) 16 (19.8 %) 0.29
  1. Data are n (%) and mean (SD). AS aortic stenosis, Dw dry weight, Zn serum zinc, ALB serum albumin, Hb serum hemoglobin level, Cre serum creatinine, Ca serum calcium corrected by serum albumin, P serum phosphate, Ca × P product of Ca and P, P ave average value of serum phosphate during this study, K serum potassium, Mg serum magnesium, Cu serum cupper, iPTH serum intact parathyroid hormone, LDL-chol serum low-density lipoprotein cholesterol, TAC-BUN time-averaged concentration of blood urea nitrogen, SBP systolic blood pressure, ACE/ARB angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker, P absorbents phosphorus adsorbents, IHD ischemic heart disease, CVD cerebrovascular disease, ASO arteriosclerosis obliterans
  2. aNumber of different P absorbents taken by patients